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g/10.1016Abstract The anticancer activity demonstrated by genetically attenuated invasive Shigella ﬂex-
neri contradicts the long-held understanding of bacterial infection-mediated anticancer activity
(BIMAc), as a ‘by-stander effect’ caused by an immune response against any invading pathogen
as a reason for tumour regression. Similarly, the selective tumouricidal effect by Salmonella A1
auxotrophic mutant in nude mice is another observation where the current theory fails. Consid-
ering these ﬂaws, we set to re-examine the mechanisms behind BIMAc independent of immune
response, on the basis of molecular understanding about the initial colonisation of gut epithelium
by S. ﬂexneri and its production of cell-cycle-inhibiting proteins called cyclomodulins. During
infection, S. ﬂexneri injects OspE effector protein into the gut epithelium. The resulting interac-
tion of OspE with ILK prevents epithelial cell exfoliation and facilitates the pathogen’s colonisa-
tion of the gut. This interaction is also shown to enhance membrane retention of ILK in these
infected cells. Correspondingly, another study reports the indispensable role of ILK in survival
of cancer cells with supernumerary centrosomes by localising it to the centrosomes and clustering
them into a bipolar spindle. Knockdown of ILK in these cells leads to apoptosis due to multipo-
lar mitosis. From these cumulative facts we hypothesised that enhanced membrane retention of
ILK in Shigella-infected cancer cells prevents localisation of ILK to centrosomes and provokes
multipolar mitosis and therefore cell death in cancer subpopulations with supernumerary centro-
somes. This interaction may also be metastasis suppressive, because of its inhibitory effect on the
focal adhesion turnover of gut epithelium, which is quintessential for any form of cell migration.
Apart from these, Shigella also encodes potent cell-cycle-inhibiting effector molecules such as
cyclomodulins. The additive action of these cyclomodulins along with the OspE–ILK interaction
may be considered as the reason behind the anticancer activity mediated by Shigella infection.
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The beneﬁcial effects of bacterial infection in a clinical sce-
nario were ﬁrst effectively exploited by William B. Coley, cir-
ca 1891. He administered a heat-attenuated mixture of
bacteria called ‘Coley’s toxin’ to cure inoperable malignan-
cies, of which the mixture of Streptococcus and Serratia mar-
scenecs was most effective. Despite the controversies
surrounding the use of Coley’s toxin, he is regarded as the
‘Father of immunotherapy’ [1]. Apart from the seminal ﬁnd-
ings of Coley, the idea of using live-attenuated bacteria as
anticancer agent was also established gradually [2]. Clostrid-
ium [3,4], Salmonella [5–7], and Shigella [8,9] are some exam-
ples of live-attenuated bacteria being pursued for their
antitumour activity and their use as pro-drug delivery vec-
tors. A tumour’s primitive angiogenesis and microenviron-
ment making it vulnerable to a generic immune response
like hyperthermia (which is provoked by repeated administra-
tion of Coley’s toxin or bacterial infection) is held as the pre-
dominant theory (cause) behind bacterial infection-mediated
anticancer activity (BIMAc) [10]. In an earlier study, the anti-
cancer activity of a genetically attenuated invasive Shigella
ﬂexneri was compared with a non-invasive mutant, using
murine breast cancer model [8]. It was observed that the
non-invasive mutant was unable to elicit any anticancer activ-
ity which is counter-intuitive to the current theory, which
claims the immunogenicity of bacteria as a reason for the
anticancer activity. In a separate study, the selective tumouri-
cidal effect by a Salmonella A1 auxotrophic mutant in xeno-
graft tumours in nude mice [5,6] was observed. This further
questions the veracity of the claim that immunogenicity is
the main mechanism of BIMAc, since these mice are devoid
of a functional immune system. Considering these caveats
in the present understanding, we set out to re-examine the
mechanism(s) behind BIMAc based on the recently elucidated
molecular understanding about Shigella’s initial colonisation
of gut epithelium [11] and effects of its cell-cycle-inhibiting
cyclomodulins [12,13].
Initial colonisation by S. ﬂexneria of gut epithelium by targeting
integrin linked kinase (ILK) with its outer shigella protein E
(OspE) protein
Rapid exfoliation of gut epithelium acts as an innate defence
against colonisation by any pathogen [14]. S. ﬂexneri, a path-
ogenic Gram-negative bacterium responsible for Shigellosis,
overcomes this innate defence mechanism by inhibiting the
epithelial cell exfoliation. It does so by injecting its OspE pro-
tein into the epithelial cells through its type three secretary
system [T3SS]. The injected OspE docks with ILK of the
host, which inhibits focal adhesion turnover, and, thus, the
subsequent epithelial exfoliation. It was shown that OspE–
ILK docking does not result in the inhibition of its enzymatic
activity in an in vitro kinase assay, but the steric hindrance
caused by OspE docking with ILK inside the cell affects its
activity which is reﬂected by the signiﬁcant reduction in phos-
phorylation of its downstream substrate like Paxillin and fo-
cal adhesion kinase, whose phosphorylation in turn is
essential for focal adhesion turnover. Apart from this,
OspE–ILK docking enhances the membrane retention of
ILK [11].Role of ILK in inhibiting the multipolar mitosis
The presence of supernumerary centrosomes aids the process
tumourigenesis in various ways [15–17]. However, the status
of a cell containing supernumerary centrosomes is in jeopardy
due to the inherent risk of multipolar mitosis which can occur,
thus leading to cell death [18]. ILK plays a vital role in prevent-
ing multipolar mitosis by clustering the supernumerary centro-
somes to form a bipolar spindle resulting in a normal mitotic
division. Although ILK does this by regulating the phosphor-
ylation of transforming acidic coiled-coil-containing protein 3
(TACC3), which is required for centrosomes clustering
through aurora-kinase A, the physical localisation of ILK to
the centrosomes is indispensable for this process [19].
Cyclomodulins
These are a class of effector molecules produced by the bacte-
ria which have the ability to modulate (pro-proliferative or
anti-proliferative) eukaryotic cell cycles [13].S. ﬂexneri encodes
invasion plasmid antigen B (IapB) and cytolethal distending
toxin (CDT) [20]. Both of these proteins have a cell-cycle
inhibitory effect, out of which IapB accompanies OspE during
its delivery through T3SS into the host cell and speciﬁcally tar-
gets the G2/M transition in cell cycle [12], while CDT induces
cell-cycle arrest by provoking double-stranded DNA breaks
[21,22].
Hypothesis
From the above facts we hypothesise that the enhanced mem-
brane retention of ILK in Shigella infected cancer cells caused
by OspE prevents the ILK localisation to centrosomes and pro-
vokes multipolar mitosis, thus leading to cell death in the sub-
population harbouring supernumerary centrosomes. This
interaction may also result in suppression of metastasis, be-
cause of the inhibition of focal adhesion turnover on gut epithe-
lial surface, which is necessary for any form of cell migration.
Apart from these two modes of host–pathogen interactions,
Shigella also encodes potent eukaryotic cell-cycle-inhibiting
effector molecules such as IapB, CDT (collectively called cyclo-
modulins). We reason that the cumulative effects of aforemen-
tioned processes in the host–pathogen interactions are
mechanistically responsible for BIMAc by S. ﬂexneria (Fig. 1).
Evaluation of the hypothesis
We argue against the existing notion of immunogenicity-driven
anticancer activity of bacteria by hypothesising that a speciﬁc
set of molecular events involving multipolar mitosis, cell-cycle
inhibition by bacterial cyclomodulins and by restriction of cell
migration may additively be the reason for the observed phe-
nomenon. To bridge the gap between our proposed hypothesis
and its establishment as a theory, a number of experimental
validations are required. Previous studies have already estab-
lished the function and role of bacterial cyclomodulins
[13,12,21,23] as cell-cycle inhibitors. The multipolar mitosis-
inducing effect of OspE can be assessed expressing OspE in
BT549 and MDA–MB-231 cell lines which are reported to pos-
sess high frequency of supernumerary centrosome-harbouring
Figure 1 Bacterial infection mediated anticancer activity (BIMAc) – Revised hypothesis.
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investigated using migration/invasion assay in the same con-
text. However, these two experiments will only prove the role
of OspE–ILK interaction in the context of proposed molecular
outcome. To provide unequivocal evidence, a comparative
assessment of the tumouricidal effect of OspE, IapB and
CDT knockout mutants with its wild-type S. ﬂexneri has to
be performed. This proposed animal study has to be done in
both immune-competent and compromised backgrounds,
respectively, to determine the extent of contribution of immu-
nogenicity-independent mechanism discussed here.Discussion
The notion of using live-attenuated bacteria for anticancer
potential has gradually evolved from the advent of Coley’s
toxin,[1] followed by the use of Clostridium novyi-NT [2],
S. ﬂexneri [7], Vnp20009 [6] and right to the development
of highly efﬁcient auxotrophic mutants of salmonella [4,5].
In spite of these advances, the underlying explanation for
the infection-mediated anticancer activity is superﬁcial, being
attributed to a general immune response-propelled bystander
effect on tumour mass [1], and the anaerobic nature of bac-
teria or auxotrophic mutations for its selective accumulation
in tumour mass [4,5]. Though our hypothesis ﬁts well for the
explanation of the immunity-independent effects of bacterial
infections and tumour regression, it does not account for
the scepticism that cyclomodulins (especially CDT) may be
cancer promoting [13,24]. However, all these circumstantial
speculations have to be reviewed in depth since these studies
were conducted in a system where normal physiological per-
turbation was associated with the occurrence of cancer,
whereas the idea of using pathogenic bacteria against tu-
mours already underscores the altered physiological condi-
tions which exist in cancer. Our argument parallels therationality of using any of the DNA-damaging drugs for
the chemotherapy of cancer which would invoke different re-
sponses in homeostatic proliferating cells (side effects) [25],
since the physiology differs in each case. Additionally, there
is an intrinsic checkpoint on the systemic survival of patho-
gens in areas other than tumour mass by making use of
genetically attenuated and auxotrophic mutant stains of these
pathogens, enabling us with a better measure of modulating
the clinical outcome of using these modalities [4,5,7].
Conclusion
To achieve a real bench to bedside translation for usage of
these bacteria, it is necessary to dissect the molecular under-
pinnings of their antitumour activity. This extensive under-
standing is crucial for current medical standards and
accelerating progress towards personalised molecular medi-
cine. Hence, we speculate that the proposed hypothesis and
its establishment as fact will be a gateway for further ad-
vances in the ﬁeld of using bacteria as therapeutic modules
for cancer therapy. Furthermore, cataloguing of the high-im-
pact molecular interactions such as OspE, CDT and IapB,
which are otherwise hidden under the complex crosstalk hap-
pening between host and pathogen in the context of cancer,
will lead to a system where control and ﬁne tuning of ‘BI-
MAc’ can be achieved by design of genetically altered and
targeted mutants of above-mentioned bacteria pertaining to
clinical perspectives.
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First Question: What do we already know about the
subject?
Bacterial infections in some cancer patients tend to
suppress tumour growth. Hyperthermia or other immune
responses against such bacteria are thought to be the fac-
tors responsible for BIMAc.
What does your proposed theory add to the current
knowledge available, and what beneﬁts does it have?
(A) The current hypothesis explains BIMAc at the
host–pathogenic interaction level underlining speciﬁc
molecular interactions, independent of the immune
response.
(B) Further engineering bacteria for therapeutic appli-
cations based on our hypothesis will avoid the risk of
employing or provoking any adverse immune reaction.
Third question: Among numerous available studies, what
special further study do you propose for testing the idea?
Comparing the anti-cancerous efﬁcacy of the wild-type
virulent strain to the non-immunogenic mutants will pro-
vide a direct evidence to facilitate the establishment of the
above hypothesis by clearly emphasising the contribution
of immunogenicity of the bacteria in suppressing tumour
progression to that of the proposed immune-independent
molecular interactions.Acknowledgements
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